Yan Wang, Ph.D.
Vice General Manager
Shenzhen Neptunus Interlong Biotech Co., Ltd
24/F, Building A, Neptunus Mansion, Nanyou Road
Nanshan, Shenzhen, PR China 518054
+86 755 26417329
About the Author:
Dr. Yan Wang is Researcher, Ph. D of Biochemistry at Jilin University, China. She is the current Vice General Manager of Shenzhen Neptunus Interlong Biotech Holding Co., Ltd and the Director of Genetic Engineering Laboratory in the Technology Center of Shenzhen Neptunus Group. Before joining the Shenzhen Neptunus Interlong Biotech Co., she worked at the Changchun Institute of Biological Products for many years as the Director of Genetically Engineered HB Vaccine Lab, the Director of Virology Lab and the Director of Biotechnology Lab. She once worked and studied at the National Bureau of Standards (NBS) and Merck Laboratories in the U.S.
Dr. Wang took charge of R&D and production for genetically engineered HB Vaccine (CHO), which was included by the National 85 Key R&D Program and 863 High-tech Program. She was also responsible for R&D projects including the rh GM-CSF for injection, rh IFN for injection, rh Insulin for injection, and monoclonal antibodies. Dr. Wang founded the Genetic Engineering Lab for Shenzhen Neptunus Interlong Co. and independently developed various interferon preparations, which include rh IFN_2b Vaginal Effervescent Tablets, rh IFN_2b Liposome Cream, rh IFN_2b in Buccal Tablet Form, and rh IFN_2b Eye Ointment. Most of these products have completed clinical trials and will enter the Chinese market shortly. At present, Dr. Wang is responsible for the R&D projects of influenza vaccine, rabies vaccine and rh NGF for injection. She has applied for 15 invention patents for her company and 3 of them has obtained authorizations. Her company was listed on the Hong Kong Stock Exchange Market (H share) on September 12, 2005.
Many of the R&D projects that she was involved won various state-level awards; one of them won the First-class National Science & Technology Advance Award. Most of the products she developed with her team are available in the Chinese market. Dr. Wang has published more than 50 scientific papers and has trained many Ph.D. and Master graduate students.
This paper provides an extensive overview of the Chinese biopharmaceutical industry today. The industry's development and current status are introduced and analyzed, with specific commentary regarding representative listed (public) companies, the capital market for biological drugs, and features of Chinese biological drugs. Biological drug products marketed in China, products at clinical trial stages, and products in R&D stages are discussed. In Section I, the features of marketed biological drugs, genetically engineered vaccines, blood products, diagnosis products and antibody drugs are introduced. In addition, several hundred marketed products and their main producers are listed. Section II provides an introduction of and commentary on drugs currently at the clinical trial stage. More than 100 drugs and their indications are listed in detail. Section III highlights the features of biological drugs in the R&D stage, with particular emphasis on those with intellectual property rights. The author discusses the outlook for biological drug R&D, the Chinese market, and potential internationalization. Biological drugs at the R&D stage and biological drugs authorized in China also are listed in detail. The establishment and development of traditional biopharmaceutical enterprises and products in China have lagged behind that of developed countries. Similarly, the technology and equipment used in the industry has also lagged. Despite this, traditional biopharmaceutical enterprises and products (including traditional bacterial vaccines and vaccines) have been improving, and are beginning to meet international standards as a result of favorable government policies. In fact, some biopharmaceutical vaccine products developed in China are ahead of those in European and the U.S. The biopharmaceutical industry is ranked third among China's pharmaceutical segments, generating 8% of total pharmaceutical sales revenue.